CRISPR Therapeutics Balance Sheet
NASDAQ: CRSPHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
CRISPR Therapeutics financial position
At the end of fiscal 2025, CRISPR Therapeutics reported total assets of $2.27 billion, up 1.0% from a year earlier against total liabilities of $343.4 million. Shareholders' equity stood at $1.92 billion, or 84.8% of assets. The company held $347.6 million in cash and equivalents against $0 of debt, a net cash position of $347.6 million.
The current ratio (current assets divided by current liabilities) was 13.32, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.00.
Summary generated from market data by MetaCap's automated system. Methodology
CRISPR Therapeutics balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 347.56M | 298.26M | 389.48M | 211.88M | 923.03M | 1.17B | 943.77M | 456.65M | 239.76M | 315.52M |
| Short-Term Investments | 1.63B | 1.61B | 1.30B | 1.60B | 1.46B | 521.71M | 0 | — | — | — |
| Receivables | 0 | 25.00M | 200.00M | 0 | 305.00K | 144.00K | 99.00K | 88.00K | 2.63M | 3.16M |
| Total Current Assets | 1.99B | 1.94B | 1.91B | 1.85B | 2.42B | 1.72B | 987.55M | 466.39M | 248.38M | 320.19M |
| Property, Plant & Equipment | 115.85M | 134.09M | 151.94M | 163.63M | 137.57M | 42.16M | 31.33M | 18.50M | 18.86M | 21.03M |
| Intangible Assets | — | 0 | 16.00K | 71.00K | 125.00K | 180.00K | 235.00K | 289.00K | 344.00K | 399.00K |
| Long-Term Investments | 0 | 0 | 1.97M | 53.13M | 0 | — | — | — | — | — |
| Total Assets | 2.27B | 2.24B | 2.23B | 2.24B | 2.75B | 1.83B | 1.07B | 489.02M | 271.35M | 344.96M |
| Accounts Payable | 11.14M | 14.71M | 38.15M | 27.43M | 14.82M | 9.09M | 5.94M | 5.07M | 1.64M | 4.57M |
| Total Current Liabilities | 149.12M | 87.78M | 108.79M | 121.11M | 119.88M | 94.26M | 57.11M | 27.75M | 14.51M | 22.00M |
| Long-Term Debt | 0 | — | — | — | — | — | — | — | — | — |
| Total Liabilities | 343.43M | 309.95M | 346.77M | 367.58M | 352.42M | 163.73M | 127.33M | 96.82M | 83.51M | 112.12M |
| Shareholders' Equity | 1.92B | 1.93B | 1.88B | 1.88B | 2.40B | 1.66B | 939.42M | 392.19M | 187.83M | 232.85M |
| Retained Earnings | -1.95B | -1.37B | -999.70M | -846.09M | -195.91M | -573.58M | -224.71M | -291.57M | -125.44M | -57.08M |
| Total Debt | 0 | — | — | — | — | — | — | — | — | — |
| Net Cash (Debt) | 1.98B | 1.90B | 1.69B | 1.82B | 2.38B | 1.69B | 943.77M | 456.65M | 239.76M | 315.52M |
| Shares Outstanding | 95.89M | 85.74M | 80.04M | 78.51M | 76.99M | 73.91M | 60.78M | 51.85M | 40.59M | 39.72M |
This table shows 10 annual periods of CRISPR Therapeutics's balance sheet, from FY 2025 back to FY 2016, across 17 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow CRSP's reporting calendar. What is a balance sheet?